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ABSTRACT
Purpose: We aimed to analyze the treatment outcomes of ipsilateral cervical lymph node 
(CLN)-positive breast cancer without other distant metastasis and compare the outcomes 
with those of supraclavicular lymph node (SCL)-positive breast cancer.
Methods: Seventy-eight patients with breast cancer and ipsilateral CLN metastasis above the 
supraclavicular fossa (CLN[+] group) were treated at 7 institutions (2000–2014). Seventy-
four patients received systemic chemotherapy and breast surgery followed by locoregional 
radiotherapy. Outcomes of the CLN(+) group were compared with those of the SCL(+) group, 
which included 183 patients with SCL involvement.
Results: The median follow-up duration was 55.9 months. Twenty-two regional failures were 
found in 15 patients—axillary lymph node (LN) in 8, SCL in 6, internal mammary LN in 3, 
previously involved CLN in 4, and previously uninvolved ipsilateral CLN in one patient. The 
5-year overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival 
(LRRFS), and distant metastasis-free survival (DMFS) rates were 68.6%, 46.7%, 68.4%, and 
57.0%, respectively. Neck dissection did not improve LRRFS and DFS (p = 0.86 and p = 0.26, 
respectively). Multivariate analysis showed that hormone receptor negativity and the presence 
of extracapsular extension were prognostic factors for poor DFS. On comparison with stage 
IIIC using propensity score matching, survival outcomes of the CLN(+) and SCL(+) groups 
were not different (5-year OS, p = 0.75; DFS, p = 0.88; LRRFS, p = 0.86; and DMFS, p = 0.45).
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Conclusion: The comparable clinical outcomes indicate that patients with breast cancer who 
have ipsilateral CLN metastasis without other distant metastasis may benefit from locoregional 
treatment of the ipsilateral breast and systemic therapies, as do those with N3c disease.
Keywords: Breast; Carcinoma; Neoplasm metastasis; Survival; Neoplasm staging
INTRODUCTION
The incidence of cervical lymph node (CLN) metastasis from breast cancer is as low as 1% 
[1]. Supraclavicular lymph node (SCL) metastasis was considered stage IV disease until 
2002 [2]. Brito et al. [3] demonstrated that the survival outcomes of patients with SCL 
metastasis after combined modality therapy were similar to those with stage IIIB disease and 
significantly better than patients with visceral stage IV. On the basis of these results [3,4], the 
International Union Against Cancer/American Joint Committee on Cancer (AJCC) staging 
system reclassified SCL metastasis from stage IV to stage IIIC in 2003 [5]. However, other 
CLN metastasis above the SCL is still considered to be M1 in this staging system [6].
Information on CLN metastasis is lacking due to its low incidence. To our knowledge, there 
are no cohort studies to date on the treatment outcomes of CLN metastasis above the SCL; 
thus, there is no consensus on how to manage these patients. The choice of treatment 
primarily depends on institutional preference [6]. Qin et al. [7] reported a patient with breast 
cancer and CLN metastasis who underwent modified radical mastectomy and CLN dissection 
followed by endocrine therapy. In that case report [7], the authors proposed classifying CLN 
metastasis as a locally advanced stage, which is similar to stage IIIC.
We performed a retrospective multicenter cohort study, Korean Radiation Oncology Group 
(KROG) 18-02, among patients with breast cancer who had ipsilateral CLN metastasis above 
the SCL without other distant metastasis. In this study, we evaluated the treatment outcomes 
and identified the prognostic factors in these patients. We also compared survival outcomes 
with those of patients with stage IIIC disease.
METHODS
Patients
We retrospectively recruited a total of 78 patients with ipsilateral CLN metastasis above the 
SCL, without any other distant metastasis at diagnosis (CLN[+] group), from 7 institutions; 
the patients were treated between January 2000 and December 2014. All treatments were 
conducted with curative, not palliative, intent. We excluded patients who had received prior 
thoracic radiotherapy (RT); those with other cancers except thyroid, cervical, and non-
melanoma skin cancer; and those who had not completed the planned treatment.
All patients were staged according to the 8th edition of the AJCC Cancer Staging Manual. Patients 
who received neoadjuvant chemotherapy were staged according to the clinical stage; otherwise, 
pathologic stage was used for a reasonable comparison. CLN metastasis was identified using the 
following imaging modalities: positron emission tomography-computed tomography (PET-CT) in 
72 (92.3%) patients; neck ultrasonography in 4 (5.1%) patients; and CT in 2 (2.6%) patients. Thirty-
two patients (41.0%) had a pathologic confirmation of CLN metastasis before initial treatment.
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Tumor subtypes were defined as follows. On immunohistochemical staining, tumors with 
positive hormone receptor (HR[+]: estrogen receptor and/or progesterone receptor) were 
classified as HR(+)/human epidermal growth factor receptor 2 (HER2)(−) for negative HER2 
status and as HR(+)/HER2(+) for positive HER2, regardless of the Ki-67 level. If the hormone 
receptor was HR(−) and HER2(+), the tumor was defined as the HER2-enriched type. 
Otherwise, tumors were categorized as triple negative.
Treatment
Treatments were determined by each institution. All patients except for one received systemic 
chemotherapy (either neoadjuvant or adjuvant). Sixty patients (76.9%) underwent neoadjuvant 
chemotherapy. The most frequent regimen was sequential anthracycline plus taxane (A+T) (n 
= 28), followed by concurrent A+T (n = 18), and others (n = 14). Adjuvant chemotherapy after 
breast surgery was administered in 32 patients (41.0%). The adjuvant chemotherapy regimens 
were sequential A+T (n = 15), concurrent A+T (n = 3), and others (n = 14).
Total mastectomy was performed in 50 (64.1%) patients, and 28 (35.9) patients underwent 
breast-conserving surgery. Axillary lymph node (LN) dissection was performed in 67 patients 
(85.9%), and sentinel LN biopsy was performed in only 11 (14.1%). Neck dissection was 
performed in only 35 patients (44.9%), excision in 25, selective node dissection in 6, and 
modified radical neck dissection in 4 patients.
Postoperative RT to the whole breast/chest wall and/or the SCL was administered in 75 
patients, up to a median dose of 50.4 Gy. Among these, 65 patients also received RT to the 
CLN. Among 13 patients who did not receive RT to the CLN, only 2 patients underwent neck 
dissection. In the remaining 11 patients, 10 patients received neoadjuvant chemotherapy with 
or without adjuvant chemotherapy.
All 40 patients who had an HR(+) tumor received endocrine therapy, and trastuzumab was 
administered in 31 patients.
Statistical analysis
Overall survival (OS) was defined as the interval from the date of initial treatment (the 
first day of neoadjuvant chemotherapy or surgery if patients did not receive neoadjuvant 
chemotherapy) until death from any cause. Disease-free survival (DFS) was defined as the 
time between initial treatment and any first recurrence or death from any cause. Locoregional 
relapse-free survival (LRRFS) and distant metastasis-free survival (DMFS) were defined as the 
interval from initial treatment to locoregional recurrence and distant metastasis, respectively. 
In this study, we counted the recurrence of ipsilateral CLN metastasis as regional recurrence, 
not distant metastasis.
To compare outcomes with patients who had stage IIIC disease, we analyzed the data of 
183 patients with SCL metastasis who underwent breast surgery (SCL[+] group) from a 
previous KROG 16–14 study [8], in which 353 patients were enrolled from 2000 and 2013 to 
analyze treatment outcomes of regional RT in patients with breast cancer who had SCL and/
or internal mammary LN metastasis. We also considered ipsilateral CLN recurrence in the 
KROG 16–14 data as regional recurrence.
We used the χ2 test or Fisher's exact test, where appropriate, for categorical variables and 
the independent t-test for continuous variables. The survival rates were estimated using the 
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Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazards 
model was applied in univariate and multivariate analyses. Propensity score matching of 
the CLN(+) and SCL(+) groups was performed according to histologic grade, subtypes, 
neoadjuvant and adjuvant chemotherapy, RT, and trastuzumab. The propensity score was 
generated with a multivariable logistic regression model. The CLN(+) and SCL(+) groups 
were matched at a 1:1 ratio using the nearest-neighbor method with a caliper of 0.2. A 
p-value < 0.05 was considered statistically significant. All statistical analyses were conducted 
using R version 3.4.2 (https://www.r-project.org/).
Ethical statement
This study was approved by the Institutional Review Board of each institution (Seoul National 
University Hospital, H-1712-145-909). All procedures performed in studies involving human 
participants were done in accordance with the ethical standards of the institutional and/or 
national research committee and the 1964 Declaration of Helsinki and its later amendments 
or comparable ethical standards.
Because of the retrospective design of the analysis, the requirement for obtaining informed 
consent of participants included in the study was waived.
RESULTS
Patient characteristics
Patients' baseline characteristics are shown in Table 1. Most patients (n = 73, 93.6%) had 
invasive ductal carcinoma and 51.3% of patients had a high-grade tumor. Although the most 
frequent subtype was HR(+)/HER2(−) (n = 22, 28.2%), the distribution of subtypes was 
relatively even. As for the initial T stage, 46 patients had T1–2 stage and 32 patients had T3–4 
stage. The number of pathologically involved axillary LNs was 0 in 21 patients, 1–3 in 17, and 
≥ 4 in 40 patients. Among the 21 patients with no axillary LN involvement, all except one 
received neoadjuvant chemotherapy. Multiple CLN metastases were most common, with 68 
cases of level V, followed by 21 of level IV, 12 of level III, 8 of level II, and 1 of level I; the one 
patient with level I CLN metastases received RT to the neck. Among 8 patients with level II 
CLN metastases, 4 patients were treated with neck RT. The details of local treatment for CLN 
are described in Table 2, according to the pathologic confirmation of CLN at diagnosis.
Survival and prognostic factors
The median follow-up duration was 55.9 months and ranged from 10.5 to 142.2 months. Of 
38 recurrences, distant metastasis alone (except for ipsilateral CLN) was the most frequent 
failure pattern (n = 16, 42.1%). Locoregional recurrence occurred in 7 patients, and 15 
patients developed both locoregional and distant failure. Twenty-two cases of regional failure 
occurred in 15 patients: with axillary LN in 8 patients, SCL in 6, internal mammary LN in 3, 
previously involved CLN in 4, and previously uninvolved ipsilateral CLN in one patient. The 
5-year OS, DFS, LRRFS, and DMFS rates were 68.6%, 46.7%, 68.4%, and 57.0%, respectively 
(Figure 1). There was a possibility of false positivity in 46 patients owing to the diagnosis of 
CLN metastasis using imaging alone, without a biopsy at diagnosis. We compared survival 
outcomes according to the presence or absence of a pathologic confirmation of CLN 
metastasis at diagnosis. The p-values for OS, DFS, LRRFS, and DMFS were 0.87, 0.77, 0.65, 
and 0.49, respectively.
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To identify prognostic factors, we performed multivariate analysis using variables with a 
p-value ≤ 0.10 in univariate analysis (Table 3). HR(+) status (hazard ratio [HR], 0.42; 95% 
confidence interval [CI], 0.21–0.83; p = 0.01) and extracapsular extension (ECE) (HR, 2.78; 
95% CI, 1.15–6.75; p = 0.02) were identified as independent factors of DFS. There were 
no prognostic factors identified for LRRFS. Neck dissection and RT to the neck failed to 
improve LRRFS (p = 0.86 and 1.00, respectively) or DFS (p = 0.26 and 0.22, respectively) in 
univariate analysis.
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Table 1. Baseline characteristics of 78 patients
Characteristics Categories Values
Age (yr) 51 (28–79)
Histology Invasive ductal carcinoma 73 (93.6)
Other 5 (6.4)
Grade* I–II 33 (42.3)
III 40 (51.3)




Initial T stage T1–2 46 (59.0)
T3–4 32 (41.0)
Involved axillary LNs (ypN or pN) 0 21 (26.9)
1–3 17 (21.8)
≥ 4 40 (51.3)
Lymphovascular invasion* Present 31 (39.7)
Absent 43 (55.1)
Resection margin Negative 76 (97.4)
Positive 2 (2.6)
Extracapsular extension* Present 31 (39.7)
Absent 46 (59.0)
Metastasis to the SCL Yes 74 (94.9)
No 4 (5.1)
Number of CLNs Single 21 (26.9)
Multiple 57 (73.1)
Pathologic confirmation† Done 32 (41.0)
Not done 46 (59.0)
Imaging study PET 72 (92.3)
Other 6 (7.7)





Values are presented as median (range) or number (%).
HR(+) = hormone receptor-positive; HER2 = human epidermal growth factor receptor 2; LN = lymph node; SCL = 
supraclavicular lymph node; CLN = cervical lymph node; PET = positron emission tomography.
*Available data only; †Pathologic confirmation of CLN before initial treatment; ‡Multiple counts.
Table 2. Local treatment for CLN according to the pathologic confirmation
Local treatment for CLN Pathologic confirmation (−) (n = 46) Pathologic confirmation (+) (n = 32)
Neck dissection only 0 2 (6.3)
RT to CLN only 26 (56.5) 6 (18.8)
Both 11 (23.9) 22 (68.8)
None 9* (19.6) 2† (6.3)
Values are presented as number (%).
RT = radiotherapy; CLN = cervical lymph node.
*Eight patients received neoadjuvant chemotherapy; †All patients received neoadjuvant chemotherapy.
Comparison with stage IIIC
We compared 78 patients (CLN[+] group) with 183 patients who had SCL metastasis (SCL[+] 
group) from the KROG 16–14 study. Table 4 summarizes baseline characteristics between the 
2 groups before and after propensity score matching. In the SCL(+) group, all patients received 
neoadjuvant chemotherapy, and 50.8% of patients received adjuvant chemotherapy. Postoperative 
RT was administered in all SCL(+) patients. There were no differences in treatment outcomes 
between the 2 groups, even before propensity score matching (OS, p = 0.51; DFS, p = 0.61; LRRFS, 
p = 0.18; DMFS, p = 0.68). Using the propensity score, 58 patients in the CLN(+) group were 
successfully matched with 58 patients in the SCL(+) group.
Kaplan–Meier survival curves are shown in Figure 2. The 5-year OS rates in the SCL(+) and 
CLN(+) groups were 65.8% and 62.6%, respectively (p = 0.75). The 5-year DFS rates were 
45.5% in the SCL(+) group and 45.7% in the CLN(+) group (p = 0.88). The respective 5-year 
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Figure 1. Kaplan-Meier survival curves of OS (A), DFS (B), LRRFS (C), and DMFS (D) in 78 patients. 
OS = overall survival; DFS = disease-free survival; LRRFS = locoregional relapse-free survival; DMFS = distant metastasis-free survival.
LRRFS and DMFS rates were 64.8% and 48.4% in the SCL(+) group and 64.7% and 57.4% in 
the CLN(+) group (p = 0.86 and 0.45, respectively).
DISCUSSION
The incidence of CLN metastasis from breast cancer is remarkably low [1], although there 
have been several studies [3,4,9-12] on SCL metastasis. Because no literature exists on 
guiding treatment and long-term outcome, management of these patients is controversial. 
Bisase and Kerawala [6] have reported that the current practice in the United Kingdom varies 
and there is no unified approach. This is because the question of whether CLN metastasis 
above the SCL is considered advanced locoregional stage or distant metastasis has not yet 
been addressed. Prospective trials are needed, but they are difficult to conduct considering 
the low incidence of CLN metastasis.
To the best of our knowledge, this is the first cohort study to investigate treatment outcomes 
of patients with ipsilateral CLN metastasis in the absence of other distant metastasis. All 
but one patient was treated with systemic chemotherapy before and/or after breast surgery, 
and all patients with an HR(+) tumor received endocrine therapy. RT was administered in 
all but 3 patients, suggesting that the included patients in this study received locoregional 
treatment with curative intent, as in patients with stage IIIC disease; in turn, this indicates 
that clinicians consider CLN metastasis advanced locoregional disease rather than distant 
metastasis. However, local treatment for CLN itself was not given to all of our patients.
Regarding local treatment for CLN, clinicians in the United Kingdom tend to perform 
aggressive neck surgery, such as comprehensive neck dissection [6]. Other studies [13,14] 
have also suggested that CLN excision should be performed in cases of breast or urogenital 
tract cancer. However, only 35 patients (44.9) in our study underwent neck surgery, and this 
was not associated with an improvement in DFS (p = 0.26) or LRRFS (p = 0.86). In contrast to 
the study by Pergolizzi et al. [10], which highlighted the local control effect of RT on SCL, RT 
to the CLN did not improve DFS (p = 0.22) or LRRFS (p = 1.00) in the current study.
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Table 3. Univariate and multivariate analyses of prognostic factors using the Cox proportional hazards model
Variables Disease-free survival Locoregional relapse-free survival
Univariate Multivariate Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Grade (III vs. I–II) 1.11 (0.58–2.13) 0.75 - - 1.00 (0.43–2.36) 1.00 - -
Initial T stage (T3–4 vs. T1–2) 1.04 (0.55–1.96) 0.92 - - 1.02 (0.44–2.39) 0.96 - -
Involved axillary LNs (≥ 4 vs. < 4) 2.07 (1.08–4.00) 0.03 1.13 (0.47–2.74) 0.79 2.35 (0.96–5.78) 0.06 1.73 (0.58–5.15) 0.32
LVI (present vs. absent) 1.79 (0.94–3.42) 0.08 1.58 (0.81–3.10) 0.18 1.48 (0.63–3.52) 0.36 - -
ECE (present vs. absent) 2.67 (1.41–5.05) < 0.01 2.78 (1.15–6.75) 0.02 2.47 (1.05–5.78) 0.04 1.81 (0.64–5.07) 0.26
Hormone receptor (positive vs. negative) 0.58 (0.31–1.10) 0.10 0.42 (0.21–0.83) 0.01 0.67 (0.29–1.54) 0.34 - -
No. of CLNs (multiple vs. single) 2.16 (0.95–4.90) 0.07 2.01 (0.85–4.75) 0.11 1.95 (0.66–5.79) 0.23 - -
NCT (yes vs. no) 1.11 (0.53–2.35) 0.78 - - 2.14 (0.63–7.25) 0.22 - -
Surgery (TM vs. BCS) 1.26 (0.65–2.45) 0.50 - - 0.87 (0.37–2.05) 0.76 - -
Axillary surgery (ALND vs. SLNBx) 1.21 (0.47–3.09) 0.70 - - 1.16 (0.34–3.92) 0.81 - -
Neck surgery (yes vs. no) 1.44 (0.77–2.70) 0.26 - - 1.08 (0.47–2.50) 0.86 - -
ACT (yes vs. no) 0.88 (0.46–1.67) 0.69 - - 0.65 (0.27–1.61) 0.36 - -
Trastuzumab (yes vs. no) 0.47 (0.24–0.95) 0.04 0.65 (0.30–1.41) 0.28 0.49 (0.19–1.24) 0.13 - -
RT to the CLN 2.11 (0.65–6.87) 0.22 - - 85,761,086 (0–inf) 1.00 - -
HR = hazard ratio; CI = confidence interval; LN = lymph node; LVI = lymphovascular invasion; ECE = extracapsular extension; CLN = cervical lymph node; NCT 
= neoadjuvant chemotherapy; TM = total mastectomy; BCS = breast conserving surgery; ALND = axillary lymph node dissection; SLNBx = sentinel lymph node 
biopsy; ACT = adjuvant chemotherapy; RT = radiotherapy; Inf = infinity.
According to the literature [15,16], the 5-year OS rate in patients with stage IV disease is 
26%–49%. This rate is much lower than the 68.6% 5-year OS rate observed in patients with 
CLN metastasis of the current study. The 5-year OS rate in our study population was similar 
to that in patients with stage IIIC disease. There were also no differences in other outcomes 
between patients with CLN(+) and SCL(+). In the study by Olivotto et al. [4], the OS rate of 
stage IIIC was intermediate between that of stage IIIB and M1 disease during the first decade. 
However, in the present study, the OS curve of the SCL(+) and CLN(+) groups overlapped 
from the beginning. This finding further supports the idea that the prognosis of CLN 
metastasis may not differ from that of SCL metastasis, and it could be hypothesized that CLN 
metastasis is simply an extension of SCL metastasis, that is, a regional LN. However, further 
studies with a larger number of patients are needed to validate this hypothesis.
We identified that the prognosis of patients with CLN metastasis was similar to that of 
patients with stage IIIC rather than M1, but the distant metastasis was still a major recurrence 
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Table 4. Baseline characteristics before and after propensity score matching
Characteristics Before PSM After PSM
SCL(+) (n = 183) CLN(+) (n = 78) p-value SCL(+) (n = 58) CLN(+) (n = 58) p-value
Age (yr) 49 (23–84) 51 (28–79) 0.35 48 (27–84) 50 (28–68) 0.34
Histology
IDC 177 (96.7) 73 (93.6) 0.41 56 (96.6) 54 (93.1) 0.68
Other 6 (3.3) 5 (6.4) - 2 (3.4) 4 (6.9) -
Grade
I–II 98 (53.6) 33 (42.3) 0.13 27 (46.6) 27 (46.6) 1.00
III 69 (37.7) 40 (51.3) - 26 (44.8) 26 (44.8) -
Unknown 16 (8.7) 5 (6.4) - 5 (8.6) 5 (8.6) -
Subtype
HR(+)/HER2(−) 68 (37.2) 22 (28.2) 0.55 18 (31.0) 17 (29.3) 0.97
HR(+)/HER2(+) 34 (18.6) 18 (23.1) - 9 (15.5) 11 (19.0) -
HER2-enriched 35 (19.1) 17 (21.8) - 12 (20.7) 11 (19.0) -
Triple-negative 46 (25.1) 21 (26.9) - 19 (32.8) 19 (32.8) -
Initial T stage
T1–2 105 (57.4) 46 (59.0) 0.92 31 (53.4) 29 (50.0) 0.85
T3–4 78 (42.6) 32 (41.0) - 27 (46.6) 29 (50.0) -
Involved axillary LNs
0 39 (21.3) 21 (26.9) 0.60 13 (22.4) 20 (34.5) 0.12
1–3 45 (24.6) 17 (21.8) - 12 (20.7) 16 (27.6) -
≥ 4 99 (54.1) 40 (51.3) - 33 (56.9) 22 (37.9) -
Chemotherapy
NCT and ACT 93 (50.8) 15 (19.2) < 0.01 14 (24.1) 14 (24.1) 1.00
NCT 90 (49.2) 45 (57.7) - 44 (75.9) 44 (75.9) -
ACT 0 (0) 17 (21.8) - 0 (0) 0 (0) -
Not done 0 (0) 1 (1.3) - 0 (0) 0 (0) -
Surgery
BCS 55 (30.1) 28 (35.9) 0.43 17 (29.3) 18 (31.0) 1.00
TM 128 (69.9) 50 (64.1) - 41 (70.7) 40 (69.0) -
Radiotherapy
Done 183 (100.0) 75 (96.2) 0.04 58 (100.0) 58 (100.0) 1.00
Not done 0 (0) 3 (3.8) - 0 (0) 0 (0) -
Trastuzumab
Done 54 (29.5) 31 (39.7) 0.14 22 (37.9) 22 (37.9) 1.00
Not done 129 (70.5) 47 (60.3) - 36 (62.1) 36 (62.1) -
Endocrine therapy
Done 100 (54.6) 40 (51.3) 0.72 27 (46.6) 28 (48.3) 1.00
Not done 83 (45.4) 38 (48.7) - 31 (53.4) 30 (51.7) -
Values are presented as median (range) or number (%).
PSM = propensity score matching; SCL = supraclavicular lymph node; CLN = cervical lymph node; IDC = invasive ductal carcinoma; HR(+) = hormone receptor-positive; 
HER2 = human epidermal growth factor receptor 2; LN = lymph node; NCT = neoadjuvant chemotherapy; ACT = adjuvant chemotherapy; BCS = breast conserving 
surgery; TM = total mastectomy.
pattern. Thirty-one patients (39.7%) experienced distant metastasis, excluding ipsilateral CLN 
metastasis during the disease course, although all patients except one underwent systemic 
chemotherapy. Therefore, proper chemotherapy is emphasized in these patients, and further 
investigations are needed to overcome distant failures. In addition, we determined that HR(−) 
and ECE(+) are prognostic factors for poor DFS; previous studies [17,18] have also identified 
these as risk factors. Treatment intensification may be needed for patients with these risk 
factors. However, it is difficult to recommend a specific treatment strategy for this population 
based on the limited number of patients. In this study, we enrolled a selective population 
treated with curative intent, as in locally advanced breast cancer. However, the role of local 
treatment for CLN metastasis was not demonstrated. Further research is needed on the 
optimal local and systemic therapies for patients with CLN metastasis.
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Figure 2. Kaplan-Meier survival curves of OS (A), DFS (B), LRRFS (C), and DMFS (D) comparing CLN(+) patients and patients with stage IIIC disease (SCL[+]) after 
propensity score matching. 
OS = overall survival; DFS = disease-free survival; LRRFS = locoregional relapse-free survival; DMFS = distant metastasis-free survival; SCL(+) = supraclavicular 
lymph node-positive; CLN(+) = cervical lymph node-positive.
Our study had some limitations. First, this was a retrospective study, although 7 institutions 
participated. Second, this study only covered a short follow-up period (median, 55.9 months) 
and the number of patients was small due to the low incidence. Third, 59.0% of patients 
were diagnosed with CLN metastasis using imaging only. Most patients underwent PET-CT, 
but it is possible that CLN metastasis was misdiagnosed as false positive, which may have 
influenced the outcomes. Finally, the indications of local treatment for CLN, including neck 
dissection and RT, were unclear.
In conclusion, the outcomes of patients with breast cancer who have ipsilateral CLN 
metastasis without other distant metastasis were comparable to those of patients with 
stage IIIC breast cancer; the former patients may benefit from locoregional treatment of 
the ipsilateral breast and systemic therapies with curative intent. The role of local treatment 
for CLN metastasis, such as neck surgery or RT, was unclear in the present analysis. The 
prognosis of patients with HR(−) and ECE(+) was poor, and more aggressive treatment may 
be needed in these patients.
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